Market revenue in 2021 | USD 552.9 million |
Market revenue in 2030 | USD 1,536.2 million |
Growth rate | 12% (CAGR from 2021 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Non-mammalian |
Historical data covered | 2017 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 59.69% in 2021. Horizon Databook has segmented the Latin America biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
Latin American countries are expected to exhibit high potential for biopharmaceutical CMOs & CROs market in the coming years. Expansion of international and well-established companies, such as Pharmaceutical Product Development, Inc. (PPD) and QuintilesIMS, in countries such as Brazil, Mexico, Argentina, and Chile is among the key factors expected to propel the market growth in the region.
Majority of the pharmaceutical and biopharmaceutical investments in Latin America come from the U.S. market. For instance, The US CDMOs have 55% of their operations in Mexico. Presence of skilled personnel and funding from government organizations in Mexico is making it one of the profitable destinations for outsourcing biopharmaceutical manufacturing services.
Moreover, major biopharma & pharmaceutical companies are opting for outsourcing services as a viable strategy to maintain their competitiveness in the market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America biopharmaceutical cmo and cro market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account